Table 2.
Relationship between Nampt/PBEF/visfatin expression in whole blood and clinicopathological features of CRC.
| Parameter | N | Nampt/PBEF/visfatin | p value |
|---|---|---|---|
| Sex distribution, F/M ratio | 36 | CRC patients: 8/28 | 0.367 |
| 54 | Controls: 18/36 | ||
| Age, median (range) | CRC patients: 62 (33–92) | <0.001 | |
| Controls: 36.5 (18–78) | |||
| Disease stage: | 0.126 | ||
| I | 3 | 0.482 (0.11–2.06) | |
| II | 11 | 0.824 (0.54–1.26) | |
| III | 18 | 0.852 (0.65–1.12) | |
| IV | 3 | 1.505 (0.75–3.06) | |
| Not determined | 1 | 1.108 | |
| Local advancement (T): | 0.090 | ||
| T2 | 4 | 0.495 (0.23–1.06) | |
| T3 | 13 | 0.809 (0.55–1.19) | |
| T4 | 19 | 0.984 (0.77–1.25) | |
| Lymph node metastases (N): | 0.232 | ||
| N0 | 15 | 0.713 (0.52–0.98) | |
| N1 | 13 | 0.915 (0.64–1.31) | |
| N2 | 8 | 1.076 (0.69–1.67) | |
| Distant metastases (M): | 0.073 | ||
| M0 | 32 | 0.798 (0.65–0.98) | |
| M1 | 3 | 1.505 (0.75–3.03) | |
| Mx | 1 | 1.108 | |
| Anemia: | 0.069 | ||
| Nonanemic | 21 | 0.732 (0.56–0.96) | |
| Mild/moderate anemia | 15 | 1.045 (0.80–1.37) |
Data presented as means with 95% CI of normalized (against geometric mean of SDHA and TBP expression) relative (referred to as mean expression across sample set investigated) quantities of Nampt/PBEF/visfatin, calculated by qBasePLUS software.